Lifeward acquires Oramed's POD tech; Oramed gets up to 49.99% LFWD stake; up to $47M capital

Lifeward Ltd.

Issues Oramed shares & pre-funded warrants for 49.99% fully diluted equity (max 45% post-closing).
Up to $47M from Oramed & another investor via $20M convertible notes (8% interest, 100% warrant coverage) and equity.
Oramed to receive 4% of ReWalk net sales for up to 10 yrs; board expands to 6 (2 each from LFWD, Oramed, 2 external).
Oramed funds/manages POD clinical program; $10M note funded at close, second $10M conditional on revenue or share price milestone.
Transaction subject to shareholder approval; 120-day lock-up for officers, directors, and Oramed shares.

item 1.01 item 2.03 item 3.02 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lifeward Ltd. entered into Share Purchase Agreement with Oramed Pharmaceuticals, Inc. (effective 2026-01-12).

Action: entry
Agreement: merger
Counterparty: Oramed Pharmaceuticals, Inc.
Effective: 2026-01-12

Exact text from the filing

On January 12, 2026, Lifeward Ltd. (the “Company,” “we” or “us”) entered into a Share Purchase Agreement (“Share Purchase Agreement”) with Oramed Pharmaceuticals, Inc. (“Oramed”) and Oratech Pharma, Inc. (“Oratech”) pursuant to which the Company agreed to acquire all of the outstanding equity interests in Oratech, a wholly owned subsidiary of Oramed (the “Oratech Share Purchase”).

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

Lifeward Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-26-000132

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.